Why the study?
Does L-NAME inhibit parasympathetic coronary vasodilation in a dog model?
Does L-NAME inhibit parasympathetic coronary vasodilation in a dog model?
Parasympathetic coronary vasodilation caused by acetylcholine and vagal stimulation is dependent on endothelium-derived relaxing factor (EDRF).
Answers are grounded in this paper and cite their sources.
Confirms EDRF dependence of parasympathetic coronary vasodilation in dogs; leaves open human translation and clinical relevance.
Vasodilation following the infusion of acetylcholine is due to the release of endothelium-derived relaxing factor (EDRF). However, the role of EDRF in neurogenic coronary vasodilation, when acetylcholine is released outside the vessel at the adventitial-medial junction, has not been established. The action of EDRF in parasympathetic coronary vasodilation was tested in the present study using a specific inhibitor of EDRF synthesis, nitro-L-arginine methyl ester (L-NAME). Experiments were conducted on closed-chest, alpha-chloralose-anesthetized dogs with the heart paced at a constant rate. Phentolamine and propranolol were administered to block alpha- and beta-adrenergic receptors, and ibuprofen was given to inhibit prostaglandin synthesis. Intracoronary infusion of L-NAME decreased the coronary vasodilation in response to intracoronary acetylcholine or vagal stimulation. The coronary response to the endothelium-independent vasodilator nitroglycerin was unaffected by L-NAME. These data demonstrate that L-NAME specifically inhibits coronary vasodilation caused by acetylcholine and vagal stimulation, indicating that parasympathetic coronary vasodilation is dependent on EDRF.
No takes yet. Share an insight, caveat, or question.
Broten et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: